Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with tacrolimus
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Burroughs TE et al. | Diabetic complications associated with new-onset diabetes mellitus in renal transplant recipients. | 2007 | Transplantation | pmid:17452891 |
Neuhaus P et al. | Comparison of FK506- and cyclosporine-based immunosuppression in primary orthotopic liver transplantation. A single center experience. | 1995 | Transplantation | pmid:7530868 |
Méndez A et al. | Pharmacokinetic study of conversion from tacrolimus twice-daily to tacrolimus once-daily in stable lung transplantation. | 2014 | Transplantation | pmid:24492423 |
Eason JD et al. | Steroid-free liver transplantation using rabbit antithymocyte globulin and early tacrolimus monotherapy. | 2003 | Transplantation | pmid:12717237 |
Neylan JF | Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine. FK506 Kidney Transplant Study Group. | 1998 | Transplantation | pmid:9500626 |
Misra S et al. | Red cell aplasia in children on tacrolimus after liver transplantation. | 1998 | Transplantation | pmid:9500636 |
Hougardy JM et al. | The once-daily formulation of tacrolimus: a step forward in kidney transplantation? | 2012 | Transplantation | pmid:22234346 |
Butani L et al. | Effect of felodipine on tacrolimus pharmacokinetics in a renal transplant recipient. | 2002 | Transplantation | pmid:11793001 |
Velidedeoglu E et al. | Early kidney dysfunction post liver transplantation predicts late chronic kidney disease. | 2004 | Transplantation | pmid:15084934 |
Murase N et al. | Suppression of allograft rejection with FK506. I. Prolonged cardiac and liver survival in rats following short-course therapy. | 1990 | Transplantation | pmid:1696405 |
Leung W et al. | Long-term complete remission and immune tolerance after intensive chemotherapy for lymphoproliferative disorders complicating liver transplant. | 1999 | Transplantation | pmid:10385092 |
Demetris AJ et al. | Conversion of liver allograft recipients from cyclosporine to FK506 immunosuppressive therapy--a clinicopathologic study of 96 patients. | 1992 | Transplantation | pmid:1374944 |
Busuttil RW et al. | General guidelines for the use of tacrolimus in adult liver transplant patients. | 1996 | Transplantation | pmid:8607197 |
Esquivel CO et al. | Suggested guidelines for the use of tacrolimus in pediatric liver transplant patients. | 1996 | Transplantation | pmid:8607198 |
Guo Z et al. | In vivo effects of leflunomide on normal pancreatic islet and syngeneic islet graft function. | 1997 | Transplantation | pmid:9075844 |
Xu X et al. | FKBP12 is the only FK506 binding protein mediating T-cell inhibition by the immunosuppressant FK506. | 2002 | Transplantation | pmid:12085010 |
Cooper MH et al. | Rapamycin but not FK506 inhibits the proliferation of mononuclear phagocytes induced by colony-stimulating factors. | 1994 | Transplantation | pmid:7509089 |
Saliba F et al. | Corticosteroid-Sparing and Optimization of Mycophenolic Acid Exposure in Liver Transplant Recipients Receiving Mycophenolate Mofetil and Tacrolimus: A Randomized, Multicenter Study. | 2016 | Transplantation | pmid:27454919 |
Egawa H et al. | Isolated alkaline phosphatemia following pediatric liver transplantation in the FK506 ERA. | 1995 | Transplantation | pmid:7533958 |
Sarwal MM et al. | Promising early outcomes with a novel, complete steroid avoidance immunosuppression protocol in pediatric renal transplantation. | 2001 | Transplantation | pmid:11468528 |
Camirand G et al. | Combined immunosuppression of mycophenolate mofetil and FK506 for myoblast transplantation in mdx mice. | 2001 | Transplantation | pmid:11468532 |
Nobori S et al. | Long-term acceptance of fully allogeneic cardiac grafts by cotransplantation of vascularized thymus in miniature swine. | 2006 | Transplantation | pmid:16421473 |
Luan FL et al. | New-onset diabetes mellitus in kidney transplant recipients discharged on steroid-free immunosuppression. | 2011 | Transplantation | pmid:21242885 |
Takatsuki M et al. | Weaning of immunosuppression in living donor liver transplant recipients. | 2001 | Transplantation | pmid:11502975 |
Suzuki S et al. | Neutrophil infiltration as an important factor in liver ischemia and reperfusion injury. Modulating effects of FK506 and cyclosporine. | 1993 | Transplantation | pmid:7685932 |
McDiarmid SV et al. | Differences in oral FK506 dose requirements between adult and pediatric liver transplant patients. | 1993 | Transplantation | pmid:7685933 |
Ho ET et al. | Once-daily extended-release versus twice-daily standard-release tacrolimus in kidney transplant recipients: a systematic review. | 2013 | Transplantation | pmid:23542469 |
Shapiro R et al. | Alemtuzumab preconditioning with tacrolimus monotherapy-the impact of serial monitoring for donor-specific antibody. | 2008 | Transplantation | pmid:18431232 |
Porrini E et al. | Prediabetes in patients receiving tacrolimus in the first year after kidney transplantation: a prospective and multicenter study. | 2008 | Transplantation | pmid:18431233 |
Veroux M et al. | Impact of conversion to a once daily tacrolimus-based regimen in kidney transplant recipients with gastrointestinal complications. | 2012 | Transplantation | pmid:22298033 |
Meier M et al. | Slowing the progression of chronic allograft nephropathy by conversion from cyclosporine to tacrolimus: a randomized controlled trial. | 2006 | Transplantation | pmid:16612281 |
Strumph P et al. | The effect of FK506 on glycemic response as assessed by the hyperglycemic clamp technique. | 1995 | Transplantation | pmid:7542815 |
Stempfle HU et al. | The role of tacrolimus (FK506)-based immunosuppression on bone mineral density and bone turnover after cardiac transplantation: a prospective, longitudinal, randomized, double-blind trial with calcitriol. | 2002 | Transplantation | pmid:11889427 |
Panz VR et al. | Diabetogenic effect of tacrolimus in South African patients undergoing kidney transplantation1. | 2002 | Transplantation | pmid:11889436 |
Charney DA et al. | Plasma cell-rich acute renal allograft rejection. | 1999 | Transplantation | pmid:10515379 |
Fisher NC et al. | The clinical impact of nephrotoxicity in liver transplantation. | 2000 | Transplantation | pmid:10910259 |
Brunet M et al. | Sequential determination of pharmacokinetics and pharmacodynamics of mycophenolic acid in liver transplant patients treated with mycophenolate mofetil. | 2006 | Transplantation | pmid:16495801 |
Kessler L et al. | Tacrolimus-associated optic neuropathy after pancreatic islet transplantation using a sirolimus/tacrolimus immunosuppressive regimen. | 2006 | Transplantation | pmid:16495816 |
Chen H et al. | Compromised kidney graft rejection response in Vervet monkeys after withdrawal of immunosuppressants tacrolimus and sirolimus. | 2000 | Transplantation | pmid:10836361 |
Moffatt SD and Metcalfe SM | Comparison between tacrolimus and cyclosporine as immunosuppressive agents compatible with tolerance induction by CD4/CD8 blockade. | 2000 | Transplantation | pmid:10836388 |
Randhawa PS et al. | Clinical significance of renal biopsies showing concurrent acute rejection and tacrolimus-associated tubular vacuolization. | 1999 | Transplantation | pmid:9921801 |
Meiser BM | The best dosing for initial tacrolimus application is trough level adapted! | 2005 | Transplantation | pmid:15714162 |
Hougardy JM et al. | Conversion from Prograf to Advagraf among kidney transplant recipients results in sustained decrease in tacrolimus exposure. | 2011 | Transplantation | pmid:21192316 |
Miao G et al. | Development of donor-specific immunoregulatory T-cells after local CTLA4Ig gene transfer to pancreatic allograft. | 2004 | Transplantation | pmid:15257039 |
Wang X et al. | Immunosuppression with a combination of pg490-88 and a subtherapeutic dose of FK506 in a canine renal allograft model. | 2005 | Transplantation | pmid:15940043 |
Markus PM et al. | Prevention of graft-versus-host disease following allogeneic bone marrow transplantation in rats using FK506. | 1991 | Transplantation | pmid:1718063 |
Ryu S and Yasunami Y | The necessity of differential immunosuppression for prevention of immune rejection by FK506 in rat islet allografts transplanted into the liver or beneath the kidney capsule. | 1991 | Transplantation | pmid:1718064 |
Wiesner RH | A long-term comparison of tacrolimus (FK506) versus cyclosporine in liver transplantation: a report of the United States FK506 Study Group. | 1998 | Transplantation | pmid:9734494 |
Chan L et al. | Optimal everolimus concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients. | 2010 | Transplantation | pmid:20517177 |
Hodak SP et al. | QT prolongation and near fatal cardiac arrhythmia after intravenous tacrolimus administration: a case report. | 1998 | Transplantation | pmid:9734501 |